

# Prophage-Stimulated Toxin Production in *Clostridium difficile* NAP1/027 Lysogens<sup>∇†</sup>

Ognjen Sekulovic, Mathieu Meessen-Pinard, and Louis-Charles Fortier\*

Département de Microbiologie et d'Infectiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Québec J1H 5N4, Canada

Received 6 July 2010/Accepted 17 March 2011

**TcdA and TcdB exotoxins are the main virulence factors of *Clostridium difficile*, one of the most deadly nosocomial pathogens. Recent data suggest that prophages can influence the regulation of toxin expression. Here we present the characterization of  $\phi$ CD38-2, a *pac*-type temperate *Siphoviridae* phage that stimulates toxin expression when introduced as a prophage into *C. difficile*. Host range analysis showed that  $\phi$ CD38-2 was able to infect 99/207 isolates of *C. difficile* representing 11 different PCR ribotypes. Of 89 isolates corresponding to the NAP1/027 hypervirulent strain, which recently caused several outbreaks in North America and Europe, 79 (89%) were sensitive to  $\phi$ CD38-2. The complete double-stranded DNA (dsDNA) genome was determined, and a putative function could be assigned to 24 of the 55 open reading frames. No toxins or virulence factors could be identified based on bioinformatics analyses. Our data also suggest that  $\phi$ CD38-2 replicates as a circular plasmid in *C. difficile* lysogens. Upon introduction of  $\phi$ CD38-2 into a NAP1/027 representative isolate, up to 1.6- and 2.1-fold more TcdA and TcdB, respectively, were detected by immunodot blotting in culture supernatants of the lysogen than in the wild-type strain. In addition, real-time quantitative reverse transcriptase PCR (qRT-PCR) analyses showed that the mRNA levels of all five pathogenicity locus (PaLoc) genes were higher in the CD274 lysogen. Our study provides the first genomic sequence of a new *pac*-type *Siphoviridae* phage family member infecting *C. difficile* and brings further evidence supporting the role of prophages in toxin production in this important nosocomial pathogen.**

*Clostridium difficile* is a Gram-positive, strictly anaerobic, spore-forming bacillus that causes infections with various symptoms ranging from asymptomatic carriage to fulminant diarrhea and pseudomembranous colitis (44). *C. difficile* infection is the most frequent cause of antibiotic-associated nosocomial diarrhea in industrialized countries (19). This opportunistic pathogen has caused severe outbreaks in North America and Europe over the last 8 years (22, 24, 38). TcdA and TcdB exotoxins are the main virulence factors of *C. difficile* and are encoded on a 19.6-kb chromosome region called the pathogenicity locus (PaLoc), which is found in all toxigenic isolates (44). A hypervirulent epidemic strain, called BI/NAP1/027, was shown to produce 16 times more TcdA and 23 times more TcdB *in vitro* than other isolates (45). The increased toxin production is thought to be responsible for the greater disease severity and higher mortality rates reported for patients infected with this particular strain (22, 24, 38).

The expression of *C. difficile* toxins is growth phase dependent. This regulation is achieved through the expression of TcdR, an alternative sigma factor that acts as a positive regulator of toxin expression, and TcdC, an early-expressed anti-sigma factor that prevents the TcdR-containing RNA polymerase from binding to toxin promoters (9, 29, 30, 32). A number

of deletions were reported in the *tcdC* gene from various clinical isolates (6). A particular 1-bp deletion causing a –1 frameshift mutation and the expression of a truncated protein could possibly explain the increased toxin production observed *in vitro* for the NAP1/027 epidemic strain (6, 27, 32, 45).

Temperate bacteriophages (or simply phages) have played a determinant role in the virulence and evolution of major bacterial pathogens (5). Temperate phages can lead to lysogeny, which occurs when the phage integrates into the bacterial chromosome and remains as a “latent” prophage. During this lysogenic cycle, prophages sometimes modify the phenotype of their host, for example, by expressing highly potent toxins, like the Shiga toxins (Stx) in *Escherichia coli*, the cholera toxin (CT) in *Vibrio cholerae*, or the botulinum neurotoxins (BoNTs) in *Clostridium botulinum* (5).

A number of phages infecting *C. difficile* have been isolated and partially characterized so far (7, 12, 15–17, 20, 28, 34, 37, 40), and all of them are temperate. Besides the two prophages that were identified in the genome of *C. difficile* strain 630 (39), only four phages have been characterized at the molecular level, including complete genome sequencing, namely,  $\phi$ CD119 (17),  $\phi$ C2 (15),  $\phi$ CD27 (34), and  $\phi$ CD6356 (20). All of these phages are members of the *Myoviridae* family (phages with contractile tails), except  $\phi$ CD6356, which is the first and only *Siphoviridae* member (phage with a long noncontractile tail) from *C. difficile* for which a complete genome sequence is currently available (20). Hence, there is a clear lack of genomic data for this group of phages, especially those of the *Siphoviridae* family. So far, *C. difficile* phages have not been found to encode proven virulence factors or to convert nontoxigenic *C. difficile* isolates into toxin-producing lysogens (15, 17, 20, 34). Nevertheless, two recent studies suggest that phages may

\* Corresponding author. Mailing address: Département de Microbiologie et d'Infectiologie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, 3001 12e Ave. Nord, Sherbrooke, Québec J1H 5N4, Canada. Phone: (819) 564-5322. Fax: (819) 564-5392. E-mail: Louis-Charles.Fortier@USherbrooke.ca.

† Supplemental material for this article may be found at <http://jlb.asm.org/>.

∇ Published ahead of print on 25 March 2011.

somehow contribute to the regulation of toxin production in *C. difficile* (14, 18), but the clear lack of data regarding phages of *C. difficile* makes it difficult to appreciate the real impact of prophages on *C. difficile* lifestyle and virulence.

In a previous study, we identified  $\phi$ CD38-2, a temperate *Siphoviridae* phage induced from a *C. difficile* clinical isolate (12). Here, we provide the full characterization of this phage, including whole genome sequencing and phenotypic characterization of lysogens. We also provide additional evidence supporting that prophages contribute to the virulence of this important nosocomial pathogen.

## MATERIALS AND METHODS

**Bacteria and growth conditions.** All strains used in this study were isolated from human fecal samples kindly provided by Louis Valiquette of the Université de Sherbrooke. Strain CD274, the host strain for  $\phi$ CD38-2, has all the characteristics of the BI/NAP1/027 hypervirulent strain (binary toxin positive, PCR ribotype 027, *tcdC* deletion at position 117). Bacteria were routinely grown inside a ThermoForma model 1025 anaerobic chamber (Fisher Scientific) under anaerobic atmosphere (10% H<sub>2</sub>, 5% CO<sub>2</sub>, and 85% N<sub>2</sub>) at 37°C in prereduced brain heart infusion (BHI) broth (Oxoid) or in TY broth (3% tryptose, 2% yeast extract, pH 7.4).

**Bacterial DNA extraction and PCR ribotyping.** Three milliliters of an overnight *C. difficile* culture was centrifuged, and total genomic DNA was extracted using an Illustra bacterial genomic DNA extraction kit following the manufacturer's recommendations (GE Healthcare). PCR ribotyping was performed on an Eppendorf Mastercycler with 20 ng purified DNA and primers published by Bidet et al. (3), with modifications described previously (12). Band patterns were analyzed and compared using GelComparII (Applied Maths).

**Prophage induction and phage propagation.** Phage  $\phi$ CD38-2 was isolated from a mitomycin C induction lysate (12). Three rounds of purification from single plaques were performed using the double agar overlay method (13) and 0.5 ml of a log-phase culture (optical density at 600 nm [OD<sub>600</sub>] of 0.4) of *C. difficile* strain CD274 as the sensitive host. The addition of 10 mM CaCl<sub>2</sub> and 0.4 M MgCl<sub>2</sub> into the soft agar was required to obtain plaques. For routine prophage induction, 10  $\mu$ l of serial 10-fold dilutions of an overnight culture of *C. difficile* was spotted onto a BHI agar plate and incubated for 4 h at 37°C under anaerobic atmosphere to allow cells to reach the log phase. Plates were then irradiated under UV light (302 nm) for 10 s on a standard UV Transilluminator (GE Healthcare). A soft agar overlay was then poured on top of the plates as described above. Clear zones in the bacterial lawn were indicative of a successful prophage induction. Phages were then purified from an agar plug as described above. Standard procedures were used for amplification in BHI broth. CaCl<sub>2</sub> and MgCl<sub>2</sub> were added to a final concentration of 10 mM each, and phage titers were determined by the soft agar overlay method described above. Titers of  $\geq 10^9$  PFU/ml were easily obtained with this method.

**Transmission electron microscopy (TEM).** Phage particles were washed with 0.1 M ammonium acetate, pH 7.5, deposited onto 400-mesh Formvar/carbon-coated copper grids (Cedarlane Laboratories), and negatively stained with 2% uranyl acetate (UA) as described before (12). The grids were observed at 60 kV with a Hitachi H-7500 transmission electron microscope equipped with a 1,000-by 1,000-pixel digital camera controlled with AMT software (Advanced Microscopy Techniques).

**Host range determination and one-step growth curve assays.** A spot test on soft agar overlays prepared as described above was used to determine the host range of  $\phi$ CD38-2, with 10  $\mu$ l of a 10-fold-diluted phage lysate and a collection of 207 clinical isolates representing 41 different PCR ribotypes. For one-step growth curve assays, cells were grown in prereduced BHI broth until the OD<sub>600</sub> reached 0.8. Then, a phage aliquot was added to 2 ml of bacterial culture to obtain a multiplicity of infection (MOI) of 0.05. CaCl<sub>2</sub> and MgCl<sub>2</sub> were added to a final concentration of 10 mM each, followed by a 5-min incubation at 37°C to allow adsorption. One milliliter of the cell suspension was washed three times with prereduced BHI broth to remove nonadsorbed phages. Serial 10-fold dilutions were then made in 10 ml BHI broth containing 10 mM CaCl<sub>2</sub> and MgCl<sub>2</sub> and incubated at 37°C under anaerobic atmosphere. Aliquots were taken at fixed intervals over 180 min, and phage titers were determined as described above. The burst size was calculated as follows: (final phage titer – initial phage titer)/initial phage titer.

**Analysis of structural proteins by SDS-PAGE and mass spectrometry.** Phage particles from a 1-liter cleared lysate ( $\sim 10^9$  PFU/ml) were purified by two

successive rounds of discontinuous cesium chloride gradient, as described previously (11). Twenty microliters of purified phage particles ( $5 \times 10^{11}$  PFU/ml) was analyzed on a 12% denaturing SDS-polyacrylamide gel as described before (11). After Coomassie blue staining, protein bands were cut out of the gel, digested with trypsin, and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS-MS) at the Proteomics Platform of the Génomique Québec Innovative Center at McGill University (Montréal, Québec, Canada).

**Phage DNA purification, restriction analysis, and Southern hybridization.** Small-scale preparations of whole phage DNA were obtained from cleared lysates by using a rapid miniprep protocol described elsewhere (35). For larger preparations, a maxi-Lambda DNA purification kit was used following the manufacturer's recommendations (Qiagen). Phage DNA was digested with various restriction enzymes (NEB, Roche), including EcoRV, HaeII, HindIII, and SmaI, and the digested products were heated at 75°C for 10 min and immediately run through a 0.8% agarose gel. Gels were stained with ethidium bromide, exposed to UV, and photographed using an ImageQuant 300 gel documentation system (GE Healthcare). Southern blot hybridizations were performed on restricted DNA as described before, with digoxigenin (DIG)-labeled probes consisting of PCR product A or B (primer sequences in Table S1 in the supplemental material) or whole phage genomic DNA (12).

**Phage genome sequencing and bioinformatics analysis.** Whole phage genome sequencing and assembly were performed on a Roche 454 GS-FLX platform using the Titanium chemistry at the Génomique Québec Innovation Center of McGill University (Montréal, Québec, Canada). Additional sequencing reactions were done directly on purified phage DNA with specific primers on an Applied Biosystems ABI 3730xl sequencer at the genomic platform of the CHUL research center (Québec, Canada). Additional sequence assembly was done using the Gap v4.10 application of the Staden package v1.6.0. Some editing was also done using BioEdit v7.0.5.3 and Artemis 11.22. Putative open reading frames (ORFs) were predicted using GeneMark.hmm for Prokaryotes v2.4 and Glimmer v3.02. The predicted proteins were compared with the BLASTp tools of the NCBI (2) and ACLAME (23) databases. Structural features and domains in predicted proteins were identified using InterProScan.

**Isolation of lysogens.** Lysogens were created using a modified soft agar overlay method. Briefly, 0.1 ml of a  $\phi$ CD38-2 lysate ( $\sim 10^8$  PFU/ml) was incorporated into BHI soft agar containing CaCl<sub>2</sub> and MgCl<sub>2</sub> that was then poured over BHI agar plates. Serial 10-fold dilutions of a log-phase (OD<sub>600</sub> of 0.4) sensitive host were spread over this phage lawn and incubated overnight at 37°C under anaerobic atmosphere. Five phage-resistant colonies were picked and restreaked 3 times onto BHI agar plates without phages to purify the lysogens. The presence of the prophage in each lysogen was confirmed by PCR and Southern hybridization, and prophage functionality was assessed by UV induction followed by phage isolation, DNA extraction, and HindIII restriction profiling as described above.

**Detection of toxins A and B.** An overnight preculture of *C. difficile* in TY broth was used to inoculate a fresh tube of the same broth (3% inoculum). Cells were grown as described above, and the OD<sub>600</sub> was monitored over a 24-h period. Aliquots were taken at 2, 8, 12, 18, 24, and 48 h postinoculation. For extracellular toxin detection, cells were removed by centrifugation, and cleared supernatants were stored at –20°C until analysis. For intracellular toxin detection, bacteria from a 10-ml culture sample were collected by centrifugation and suspended in 0.5 ml phosphate-buffered saline (PBS). Cells were then broken with glass beads ( $\leq 106 \mu$ m; Sigma) using a FastPrep apparatus (MP Biomedicals). The lysate was cleared by centrifugation, and the supernatant was stored at –20°C until analysis. Detection of the toxins was done on appropriate dilutions using an enzyme-linked immunosorbent assay (ELISA) (Premier Toxins A and B kit; Meridian Biosciences), as recommended by the supplier. The ELISA unit definition corresponds to the absorbance at 450 nm of the ELISA reaction multiplied by the dilution factor and converted to a volume of 1 ml of cells (intracellular toxins), culture supernatant (extracellular toxins), or a combination of both (total toxins). An immunodot blot method was used to specifically detect TcdA and TcdB. For this, culture supernatants were serially diluted in TY broth and directly spotted (0.1 ml) onto nitrocellulose membranes using a 96-well dot blotter apparatus. All wells were washed twice with PBS, after which the membrane was allowed to air dry for 30 min. Toxins were detected with monoclonal anti-TcdA or anti-TcdB mouse antibody (Meridian Life Science) at a 1:3,000 or 1:1,000 dilution, respectively. A secondary anti-mouse IgG horseradish peroxidase (HRP)-linked antibody (Cell Signaling) was used at a 1:3,000 dilution, and the membranes were revealed with an ECL Plus Western blotting detection system (GE Healthcare) as recommended by the manufacturer, followed by exposition to Hyperfilm ECL autoradiography films (GE Healthcare) (33). Spot intensities were compared using ImageJ 1.42q software (<http://rsbweb.nih.gov/ij/>).




FIG. 1. TEM picture of  $\phi$ CD38-2 negatively stained with 2% uranyl acetate. Bar, 100 nm.

**RNA extraction and gene expression analysis.** Total RNA was extracted from 10-ml culture samples after two successive treatments with TRIzol (Invitrogen). Cells were broken during the first treatment by adding glass beads ( $\leq 106 \mu\text{m}$ ; Sigma) and using a FastPrep apparatus (MP Biomedicals). Total RNA was dissolved in RNase-free water, and 10  $\mu\text{g}$  was treated with 6 units of RNase-free Turbo DNase I (Ambion) for 30 min at 37°C, as recommended by the manufacturer. The absence of contaminating genomic DNA was verified by performing a 40-cycle PCR with primers targeting the 16S rRNA gene in the presence of 200 ng total RNA. First-strand cDNA synthesis was performed on 3  $\mu\text{g}$  total RNA using SuperScriptII RT (Invitrogen) with random primers (Promega) according to the manufacturer's specifications. Real-time quantitative reverse transcriptase PCRs (qRT-PCRs) were performed on a Mastercycler EP Realplex instrument (Eppendorf) in a total volume of 10  $\mu\text{l}$ , with the following components: 1 $\times$  PCR buffer (12 mM Tris-HCl, pH 8.3, 50 mM KCl, 8 mM MgCl<sub>2</sub>, 150 mM trehalose, 0.2% Tween 20, 0.2 mg/ml bovine serum albumin [BSA], 0.2 $\times$  SYBR green [Roche]), 150 ng of template cDNA, and one of the primer sets specific for *tcdA*, *tcdB*, *tcdC*, *tcdR*, *tcdE*, or the 16S rRNA gene (see Table S1 in the supplemental material). The cycling conditions were as follows: 95°C for 2 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The  $\Delta\Delta\text{CT}$  (threshold cycle) comparative method was used to calculate the relative expression of each gene, with the 16S rRNA gene as the reference gene.

**Nucleotide sequence accession number.** The complete genome sequence of  $\phi$ CD38-2 has been submitted to GenBank under the accession number HM568888.

## RESULTS

**Phage isolation.** We have previously reported the induction of two temperate phages,  $\phi$ CD38-1 and  $\phi$ CD38-2, after mitomycin C treatment of CD38, a clinical isolate of *C. difficile* (12). Several *C. difficile* isolates were found to be sensitive to  $\phi$ CD38-2, including CD274, which has all the common characteristics of the hypervirulent NAP1/027 strain, which has caused several outbreaks in North America and Europe (ribotype 027, *tcdC* deletion, binary toxin positive). Phage  $\phi$ CD38-2 was purified from single plaques using CD274 as the host and further propagated in BHI broth to  $\geq 10^9$  PFU/ml. Transmission electron microscopy (Fig. 1) and DNA restriction profiling confirmed that the isolated phage, a member of the *Siphoviridae* family of the order *Caudovirales* (1), corresponded to the  $\phi$ CD38-2 phage that we described before (12).

**Host range and lytic growth cycle.** The host range of  $\phi$ CD38-2 was determined using a collection of *C. difficile* clinical isolates and spot tests on soft agar overlays.  $\phi$ CD38-2

infected 99 of the 207 isolates tested (48%), among which 79 (80%) corresponded to the NAP1/027 epidemic strain (PCR ribotype 027). The other, non-NAP1/027 sensitive isolates represented 10 different PCR ribotypes (see Table S2 in the supplemental material). The lytic growth cycle of  $\phi$ CD38-2 was determined on strain CD274. The latent period was 95 min, and the burst size was  $35 \pm 11$  PFU per infected cell, which is in the range reported for other *C. difficile* phages (16, 28).

**Genome sequence.** Full genome sequencing was performed on a Roche 454 GS-FLX platform. A total of 17,659 sequence reads were obtained and assembled in two large contigs totaling 40,468 bp, with an average coverage of  $\sim 90$ -fold. The two contigs were joined, and gaps were filled after sequencing reactions were performed directly on the phage DNA. The  $\phi$ CD38-2 genome is composed of a double-stranded DNA (dsDNA) molecule of 41,090 bp with a G+C content of 30.83%, which is a little above, but in the range reported for, that of other *C. difficile* phages (28.7 to 29.4%) (15, 17, 34) and of *C. difficile* strain 630 (29.06%) (39). Digestion of the purified phage DNA with various restriction enzymes gave profiles perfectly corresponding to a circular genomic map, except for a faint submolar fragment of  $\sim 0.9$  kb that was observed with EcoRV (see Fig. S1 in the supplemental material). Heating the digested DNAs at 75°C for 10 min prior to loading on the agarose gel did not reveal cohesive termini. Moreover, Southern hybridization of the restricted DNA with probe A, covering nucleotides 39450 to 40663, which we suspected to be the region containing the *pac* site, revealed the expected submolar fragments in all digestions (see Fig. S2 in the supplemental material). Thus, our data indicate that  $\phi$ CD38-2 is a *pac*-type phage that packages its DNA using a headful mechanism and that the *pac* site is located between *orf53* and *orf54*. To our knowledge, this represents the first *pac*-type *Siphoviridae* phage to be described in *C. difficile*.

**DNA homology and other similar prophages.** BLASTn analyses against the nonredundant nucleotide and whole genome shotgun databases at NCBI revealed the existence of unassembled genomic fragments nearly identical to  $\phi$ CD38-2 in two *C. difficile* isolates currently being sequenced at McGill University: strains QCD-37x79 (contig NZ\_ABHG02000044) and QCD-63q42 (contigs NZ\_ABHD02000046, NZ\_ABHD02000048, NZ\_ABHD02000049, and NZ\_ABHD02000057).

**Gene products and annotation.** Fifty-five putative *orf* genes encoding proteins of  $\geq 30$  amino acids were identified by GeneMark.hmm and Glimmer analyses using standard (ATG) and alternative (GTG, TTG, CTG) start codons. Manual validation of each *orf* was then performed, and the most probable start codon was selected based on the presence of a suitable ribosome-binding site complementary to the 3' end of the 16S rRNA gene of *C. difficile* 630 (39). A genomic map of  $\phi$ CD38-2 is presented in Fig. 2.

All predicted ORFs were translated into proteins and compared against nonredundant protein sequences from GenBank and ACLAME databases using BLASTp. Putative functions were attributed to each ORF based on BLAST results, by comparison with homologous proteins found in the ACLAME database, and based on the presence of conserved domains found through searches in the conserved domain database (CDD) at NCBI and by InterProScan analyses. Overall, a putative function could be attributed to 23 of the 55 ORFs (42%),




FIG. 2. Genetic organization of the complete  $\phi$ CD38-2 genome (41,090 bp). Predicted ORFs and their orientations are represented by arrows. Functional assignments are indicated above the ORFs, along with functional modules that were inferred based on gene annotation and whole genomic organization. Thick black arrows correspond to proteins identified by LC-MS-MS. The relative G+C content, calculated on a 10-base window along the whole  $\phi$ CD38-2 genome, is shown below the map to highlight a region of possible horizontal gene transfer (gray arrows). RBP, receptor-binding protein; SSB, single-strand binding protein.

and the best BLAST hits corresponding to gene products identified in strain QCD-37x79 are listed in Table S3 in the supplemental material, along with a second relevant hit from another source, when available (excluding hits from strain QCD-63q42). The complete genome sequence of  $\phi$ CD6356, the first *cos*-type temperate *Siphoviridae* phage described in *C. difficile*, has recently been published (20). Protein similarity was found between the lysis, lysogeny control, and DNA replication, recombination, and modification modules of phages  $\phi$ CD38-2 and  $\phi$ CD6356, but their structural genes were unrelated. Also, only a few hits corresponded to gene products from  $\phi$ CD27 and  $\phi$ CD119, thus confirming that  $\phi$ CD38-2 is completely different from all *Myoviridae* phages of *C. difficile* described so far (15, 17, 34, 39). The gene organization and modular structure of the  $\phi$ CD38-2 genome are similar to those of other *C. difficile* phages and other temperate phages infecting low-G+C bacteria (25). Key features of the  $\phi$ CD38-2 annotation are described below.

**Structural proteins.** Protein BLAST analyses showed that except for the two highly related prophages identified in *C. difficile*, strains QCD-37x79 and QCD-63q42, most structural proteins were related to other *Clostridium* genomic sequences, including *C. perfringens*, *C. botulinum*, and *C. tetani* (see Table S3 in the supplemental material). ORF18 corresponds to a tail protein with a putative endopeptidase activity and is probably the phage receptor-binding protein (RBP) responsible for host specificity. Structural proteins of CsCl-purified  $\phi$ CD38-2 particles were separated by SDS-PAGE, followed by LC-MS-MS analysis of the trypsin-digested protein bands (Fig. 3A). The experimental and calculated masses were in agreement, and peptide mapping did not reveal any evidence of posttransla-

tional proteolytic processing (Fig. 3B). Based on local genomic organization and BLAST analyses, ORF7 was annotated as the major capsid protein (MCP) and ORF17 as the major tail protein (MTP). Because the boundary between the capsid and tail morphogenesis modules could not clearly be defined, ORF12 could be either a capsid or a tail protein, and as a consequence, it was annotated as a major structural protein (MSP), without reference to any particular virion structure (Fig. 3B).

**Lysogeny control and putative lysogenic conversion genes.** In most phages infecting low-G+C Gram-positive bacteria, including *C. difficile* phages  $\phi$ C2,  $\phi$ CD27, and  $\phi$ CD119, the lysogeny module is located between the lysis cassette and the DNA replication and regulation module. This region generally encodes Cro and cI repressors, transcriptional regulators, and antirepressors, as well as the integrase (15, 17, 20, 26, 34). A lysogeny module could not clearly be defined in  $\phi$ CD38-2, and a different organization was observed. ORF39, a putative cI phage repressor based on BLAST results and on the presence of a helix-turn-helix (HTH) DNA-binding domain, was found approximately 10 kb downstream of the lysis cassette. ORF53, a phage integrase of the tyrosine recombinase/integrase family, was found 5 kb downstream of *orf39* near ORF55, a protein of the SR serine recombinase family. In  $\phi$ CD6356, a site-specific recombinase (*orf57*) is also located apart from the lysogeny module (*orf34* to *orf40*). However, in the latter case, 3 putative transcriptional regulators are clustered in the lysogeny module (*orf35*, *orf37*, and *orf38*), whereas in  $\phi$ CD38-2, we found only one.

A putative function could be assigned to only 8 (25%) of the 32 nonstructural genes (*orf24* to *orf55*), of which 4 could be




FIG. 3. Analysis of  $\phi$ CD38-2 structural proteins. (A) Coomassie brilliant blue staining of a 12% SDS-polyacrylamide gel, showing  $\phi$ CD38-2 structural proteins, along with a protein molecular mass marker (lane M). Arrows and letters on the right correspond to protein bands identified by LC-MS-MS analysis, which are further characterized in panel B.

related to DNA replication, transcription, and gene regulation. InterProScan analyses predicted the presence of a signal peptide and/or transmembrane regions within ORF32, ORF33, and ORF34, suggesting that these proteins could potentially be targeted to the membrane or be secreted. Interestingly, the  $\phi$ CD38-2 genome showed a marked deviation in its G+C content from *orf24* to *orf34*, where the average G+C content was  $25.6\% \pm 1.2\%$ , while it was  $31.6\% \pm 3.1\%$  in the rest of the genome (Fig. 2). Such deviations are often traces of past horizontal gene transfer (HGT) events. In line with this, a BLASTp analysis with ORF35 retrieved hits corresponding to DNase, including CDP07 (see Table S3 in the supplemental material), a putative DNase found on plasmid pCD630 (NCBI accession no. NC\_008226.1) carried by *C. difficile* strain 630 (39). Moreover, a nucleotide BLAST analysis revealed a region extending from positions 31112 to 32991 in  $\phi$ CD38-2 sharing 65% identity with a region from plasmid pCD630 that corresponds to  $\sim 2/3$  of the gene coding for a DNase. Taken together, these data suggest that a portion of the  $\phi$ CD38-2 genome, located next to the lysis module, has been acquired through HGT and could possibly participate in lysogenic conversion of the host. Further experiments are needed to confirm this hypothesis. Note that we performed a similar analysis with  $\phi$ C2,  $\phi$ CD27, and  $\phi$ CD119, and only the last shared significant homology (68% nucleotide identity over 794 bp) with a region coding for a methyltransferase in plasmid pCKL555A (NCBI accession no. CP000674.1) of *Clostridium kluyveri* DSM 555 (17). Interestingly, a note in the ACLAME database mentions that pCKL555A is a prophage. These observations support the idea that other phages of *C. difficile* have probably recombined with plasmids as well.

**Prophage maintenance as a circular plasmid.** The attachment site (*attP*) in most temperate phages is generally located near the integrase gene. Also, when a prophage integrates into the chromosome of its host, at least one band from the phage restriction profile shifts in the lysogen due to its fusion with bacterial DNA. In order to locate *attP* and to determine whether or not  $\phi$ CD38-2 integrates, we performed Southern blot hybridizations with DIG-labeled PCR probes covering the integrase region (probe A, *orf53* to *orf55*) and tail (probe B, *orf18* to *orf20*) genes (see Fig. S2 in the supplemental mate-

rial). We also used the whole phage genome as a probe. As can be seen in Fig. S2, the whole restriction profiles and the sizes of specific fragments detected by the two PCR probes were identical in the purified phage and in the lysogen, except for the submolar fragment that was present only in the purified phage DNA. Because no visible shift in size could be observed with any bands and since the submolar fragment was absent from the lysogen, we concluded that  $\phi$ CD38-2 did not integrate and that its genome was circular in the lysogen (see Fig. S2). Interestingly, the presence of a 1.5-kb fragment sharing 65% identity at the DNA level with the pCD630 plasmid from *C. difficile* strain 630 further supports the evidence that the  $\phi$ CD38-2 prophage replicates as a circular plasmid. Also noteworthy to mention, the two contigs from strains QCD-37x79 and QCD-63q42 that are almost identical to  $\phi$ CD38-2 were found as unassembled fragments in public databases, suggesting that they could not be associated with bacterial DNA. Finally, a ParA homolog (ORF30) similar to a *Spiroplasma citri* Soj-like protein was found in  $\phi$ CD38-2 (ParA cd02042,  $1e-3$ ; Soj COG1192,  $1e-18$ ; CbiA pfam01656,  $4e-9$ ; SopA PHA02519,  $3e-6$ ) (see Table S3 in the supplemental material). Since ParA/Soj-like proteins are involved in chromosome segregation and plasmid maintenance (31), the presence of ORF30 in  $\phi$ CD38-2 supports a role in prophage maintenance as a plasmid. To our knowledge, this represents the first example of such a prophage in *C. difficile*.

**Prophage-stimulated toxin production in  $\phi$ CD38-2 lysogens.** Previous reports have shown that toxin production in *C. difficile* can be affected by some prophages (14, 18). In order to test whether  $\phi$ CD38-2 could influence toxin production in *C. difficile*, we infected the host isolate CD274, which is a representative member of the hypervirulent strain BI/NAP1/027, to create lysogens. The growth profiles in TY broth and total biomass yields after 24 h were not significantly different between the CD274/ $\phi$ CD38-2 lysogen and the wild-type parental strain (Fig. 4A). Aliquots of cells and culture supernatants were collected at different time intervals, and intracellular and extracellular relative toxin levels were determined using a commercial ELISA. At 8 and 12 h, most of the toxins detected were intracellular, and the level increased 3-fold at 12 h, which is consistent with the entry into stationary phase. A slight and




FIG. 4. Growth and toxin production of wild-type CD274 and the CD274/ $\phi$ CD38-2 lysogen. (A) Growth of the wild type (white circles) and the lysogen (black circles) in TY broth was monitored by measuring the optical density at 600 nm over 24 h. (B) The relative amounts of TcdA and TcdB toxins were determined by a toxin A/B ELISA. Data represent the means  $\pm$  standard deviations from three independent biological replicates. Extracellular, intracellular, and total (extracellular plus intracellular) toxin levels of the wild type (WT) and the lysogen (LYS) were compared by a Student *t* test. Significant differences (\*,  $P < 0.05$ ) were observed for total and extracellular, but not for intracellular, toxins.

gradual decrease was observed afterward, but the levels did not differ significantly between the wild type and the lysogen (Fig. 4B). On the contrary, extracellular toxins accumulated faster and to a higher level in culture supernatants from the CD274/ $\phi$ CD38-2 lysogen, with 2.1-, 2.4-, and 2.0-fold more toxins than in wild-type CD274 after 12, 18, and 24 h of growth, respectively ( $P < 0.05$  at 18 and 24 h). The proportion of extracellular toxins also represented ~80 to 90% of the total toxins detected in culture samples. The amount of extracellular toxins reached a plateau at 24 h in supernatants from the wild-type strain but continued to accumulate gradually in the lysogen until 48 h (see Fig. S3 in the supplemental material). The total toxin production, expressed in ELISA units/ml of culture and obtained by combining the intracellular and extracellular toxin values, yielded 1.2-, 2.3-, and 1.8-fold higher toxin levels in the lysogen after 12, 18, and 24 h of growth, respectively ( $P < 0.05$  at 18 and 24 h) (Fig. 4B). An immunodot blotting experiment using specific anti-TcdA and anti-TcdB antibodies revealed that both toxins, in particular, TcdB, accumulated to higher levels in culture supernatants of the lysogen (Fig. 5). Densitometry analysis of the dots showed that the amounts of TcdA and TcdB were ~1.6- and 2.1-fold larger, respectively, in the




FIG. 5. Immunodot blot detection of toxins in cleared supernatants from 24-h cultures of wild-type CD274 and a CD274/ $\phi$ CD38-2 lysogen. TcdA and TcdB toxins were detected using monoclonal anti-TcdA and anti-TcdB antibodies. Each spot represents an independent biological experiment.

CD274/ $\phi$ CD38-2 lysogen than in the wild-type CD274 strain. This was consistent with the results obtained with the ELISA (Fig. 4B; also see Fig. S3 in the supplemental material).

We then performed real-time qRT-PCR assays to compare the relative expression levels of the five PaLoc genes in both strains. Total RNA was extracted from the CD274/ $\phi$ CD38-2 lysogen and the wild-type parental strain CD274 at 4, 12, 18, and 24 h postinoculation. Based on  $\Delta CT$  values (compared to that for the 16S rRNA gene), the expression profiles were consistent with what we expected. For example, the expression of *tcdR*, *tcdA*, and *tcdB* increased sharply between 4 and 12 h and then decreased gradually afterwards. Expression of *tcdC* reached its maximum at 4 h and then gradually decreased. Finally, the expression of *tcdE* remained relatively constant over the first 18 h and then decreased at 24 h (data not shown). By use of the  $\Delta\Delta CT$  relative comparison, the expression levels of all PaLoc genes were found to be similar in lysogenic and wild-type strains after 4 h of growth (ratio of ~1), but after 24 h, the levels of *tcdA*, *tcdB*, *tcdC*, *tcdE*, and *tcdR* mRNA were, respectively, 2.7-, 2.9-, 2.7-, 5.7-, and 2.7-fold higher in the lysogen than in the wild-type strain (Fig. 6). Again, these data are in agreement with the toxin levels that were detected by ELISA and immunodot blotting. Our results show that the expression patterns are similar in both strains but that the presence of the prophage leads to higher expression of all PaLoc genes.

Four additional  $\phi$ CD38-2 lysogens were created in different




FIG. 6. Relative expression of PaLoc genes in the CD274/ $\phi$ CD38-2 lysogen versus the wild-type CD274 strain at different time points. Data are presented as the fold change in gene expression in the lysogen relative to that for the wild-type strain and represent the means  $\pm$  standard errors of the means from 4 independent biological replicates. A value of 1 means that there is no difference in mRNA levels between the two strains. For each gene, the fold change at 12, 18, and 24 h was compared to the value at 4 h by using the Student *t* test (\*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ).

genetic backgrounds to verify if the above-described observations made with the CD274 lysogen could be extended to other *C. difficile* isolates. Phage  $\phi$ CD38-2 was introduced into strains CD45 (PCR ribotype 035) and CD62 (PCR ribotype 014), as well as CD66 and CD111 (both PCR ribotype 027). Toxins A and B were detected in culture supernatants using the ELISA and were comparable to levels for strain CD274 (418 ELISA units/ml), with 379, 113, 780, and 724 ELISA units/ml for strains CD45, CD62, CD66, and CD111, respectively. When the amounts of toxins produced by the corresponding lysogens were compared, only the CD45 lysogen showed a 2-fold increase in extracellular toxins after 24 h compared to the level for the wild-type strain. Toxin levels in the supernatants of the CD62, CD66, and CD111 lysogens were, respectively, 1.3-, 0.6-, and 1.3-fold the level for the wild-type strain and were not significantly different. The amounts of *tcdA* and *tcdB* transcripts were determined by real-time qRT-PCR analysis of total RNA extracted from these lysogens and the corresponding parental strain after 24 h of growth in TY broth. The detected mRNA levels were higher in the CD45/ $\phi$ CD38-2 lysogen, with 29- and 22-fold increases in *tcdA* and *tcdB* mRNA, respectively (see Fig. S4 in the supplemental material). The CD62, CD66, and CD111 lysogens showed on average 5.76/5.57-, 0.75/0.44-, and 2.14/1.32-fold differences, respectively, in toxin A/B mRNA levels compared to levels for the parental strain. Five colonies were picked at the end of each culture experiment, and the presence of the prophage was confirmed by PCR in all cases, thus excluding prophage loss as a possible explanation for the observed variability in toxin production from one lysogen to another. Taken together, our results demonstrate that  $\phi$ CD38-2 can stimulate toxin production in some lysogens, including the NAP1/027 epidemic strain, by increasing mRNA transcription and/or stability and that this effect seems to be strain dependent.

## DISCUSSION

The molecular basis for the hypervirulence and hyper-toxin-producing phenotype of the NAP1/027 epidemic strain is still unclear, and it is reasonable to presume that prophages might be involved. Here we report the microbiological and molecular characterization of  $\phi$ CD38-2, a temperate phage of the *Siphoviridae* family infecting *Clostridium difficile*, and our study provides further evidence that temperate phages can affect important virulence-associated phenotypes, like toxin production, in *C. difficile*.

The genomes of only a few phages of *C. difficile* have been fully sequenced to date. In addition, all currently available *C. difficile* phage sequences represent members of the *Myoviridae* family that are related genetically (15, 17, 34, 39). The only exception is phage  $\phi$ CD6356, a *cos*-type phage of the *Siphoviridae* family (20). The complete genome of  $\phi$ CD38-2 was sequenced, and protein comparisons revealed that the lysis and DNA replication/gene regulation modules of  $\phi$ CD38-2 and  $\phi$ CD6356 are related but that their structural genes are completely different. The fact that  $\phi$ CD38-2 is a *pac*-type *Siphoviridae* phage whereas  $\phi$ CD6356 is a *cos*-type phage confirms that they are part of two distinct phage families that package their DNA using two different mechanisms. The presence of a putative integrase gene (*orf53*) would have *a priori* suggested

that  $\phi$ CD38-2 should integrate upon lysogenization, but our experimental data support the conclusion that  $\phi$ CD38-2 maintains itself as a circular plasmid and does not integrate into the chromosome of the lysogens that we tested. Of note, the genomic organization of  $\phi$ CD6356 is very similar to that of  $\phi$ CD38-2 regarding the nonstructural genes, and it would be interesting to know whether the  $\phi$ CD6356 prophage integrates or maintains itself as a circular plasmid, but this information was not provided by the authors (20). Also, the identification of a ParA homolog in  $\phi$ CD38-2, as in  $\phi$ CD6356 and  $\phi$ C2, was interesting because ParA/Soj-like proteins are involved in chromosome segregation and plasmid maintenance (31). ParA and ParB homologs were also shown to enable the temperate phage LE1 from *Leptospira biflexa* to replicate autonomously as a circular plasmid (4). Finally, we found an  $\sim$ 1.9-kb fragment in the region encoding ParA in  $\phi$ CD38-2 that shares significant homology with the plasmid from *C. difficile* strain 630. This suggests that a past recombination event between a prophage and a plasmid occurred, leading to a chimeric phage that can autonomously replicate as a circular plasmid. To our knowledge, this represents the first example of such a prophage in *C. difficile*.

**Prophage-stimulated toxin production in NAP1/027 lysogens.** TcdR and TcdC are positive and negative regulators of toxin production in *C. difficile*, respectively (44). A number of deletions were identified in *tcdC*, in particular, a 1-bp deletion at position 117 that leads to the synthesis of a severely truncated TcdC protein in the NAP1/027 epidemic strain (6, 27). This deletion is thought to be responsible for the increased toxin production reported in this strain (45). However, recent studies suggest that deletions in *tcdC* alone cannot explain hyper-toxin production and hypervirulence of NAP1/027 isolates (36, 43). The regulation of toxin production in *C. difficile* thus seems to be complex, and other mechanisms are likely involved in this process. A previous report by Goh et al. suggested that lysogens carrying the temperate phages  $\phi$ C2,  $\phi$ C6, and  $\phi$ C8 could modify toxin production in *C. difficile* (14). Interestingly, the PaLoc shares some sequence similarity with phage proteins, in particular, TcdE, suggesting that it is probably the remains of an ancient prophage. This also suggests that phage regulatory networks could be intertwined with those of the PaLoc (14, 42). Further evidence supporting a possible interconnection between prophages and the PaLoc was recently provided by Govind et al., who showed that during lysogeny, the RepR transcriptional regulator encoded by  $\phi$ CD119 was able to bind to a promoter region in the PaLoc upstream of *tcdR*, causing a downregulation of the expression of all PaLoc genes, including *tcdA* and *tcdB* (18).

Lysogenization of CD274 with  $\phi$ CD38-2 led to 1.6- and 2.1-fold increases in toxins A and B in culture supernatants, respectively (Fig. 4 and 5). Although not dramatic, the increase was significant. Also, the levels of intracellular toxins were not very different between the two strains, and most of the toxins (80 to 90%) were found in the culture supernatant. Using a real-time qRT-PCR approach, we demonstrated that the mRNA levels of all 5 PaLoc genes were higher in the lysogen carrying  $\phi$ CD38-2 than in the wild-type strain (Fig. 6). In addition, there seemed to be greater expression of *tcdE* than of the other PaLoc genes in the lysogen. Together, these results lead us to conclude that the lysogen carrying  $\phi$ CD38-2 synthe-

sized and secreted more toxins, as a result of increased expression of PaLoc genes and especially *tcdE*. The net result is a higher extracellular toxin level in cultures of the lysogen and similar intracellular toxin levels in both strains. Our bioinformatics analyses identified only one HTH putative DNA-binding protein in the  $\phi$ CD38-2 genome (ORF39), and this protein is likely the *cI* phage repressor involved in lysogeny maintenance. The only other identifiable candidate that could possibly affect RNA transcription is a putative sigma factor (ORF52). This gene product could bind directly to promoter regions upstream of PaLoc genes and recruit the RNA polymerase to increase the rate of transcription initiation. Alternatively, it could interfere with TcdC. In the latter case, TcdC would be impaired in its ability to destabilize the TcdR-RNA polymerase holoenzyme, thus promoting transcription initiation through binding of TcdR. Because  $\phi$ CD38-2 does not seem to integrate into the chromosome of its host, disruption of a bacterial gene is unlikely to be the reason explaining the difference in PaLoc gene transcript levels. Further experiments are necessary to determine the exact mechanism leading to increased toxin expression.

Our study and those of Govind (18) and Goh (14) also showed that depending on the phage-host system and the bacterial genetic background, the impact of different prophages on toxin production varies. We found that transcription was significantly increased in some lysogens and was unaffected or slightly decreased in others (see Fig. S4 in the supplemental material). It is already known that toxin expression varies greatly from one strain to another and that several factors may participate in such regulation (10, 21). The strains we selected to create additional lysogens produced similar amounts of toxins. Hence, at least in our study, we can rule out the possibility that differences in basal toxin production explain the variable impact of  $\phi$ CD38-2 on these strains. The presence of a putative integrase gene in  $\phi$ CD38-2 suggests that the phage could potentially integrate into the chromosome of its host. However, consistent experimental evidence suggests that the  $\phi$ CD38-2 prophage replicates autonomously as a circular plasmid. Although we cannot completely exclude the possibility that this phage could integrate in some strains but not in others, the strain-dependent difference in toxin production that we observed in our study is unlikely due to gene disruption at different sites. We did not determine systematically the prophage content of the strains we used in our study, but we can confirm that strain CD111 contains at least one *Siphoviridae* phage different from  $\phi$ CD38-2 (unpublished data). We also found that strain CD274 contains a prophage of the *Myoviridae* family identical or highly similar to  $\phi$ CD5, which we previously characterized (12), and to  $\phi$ 027 from the epidemic strain R20291 (41) (NCBI accession no. accession number NCO13316). It is thus possible that multiple synergistic and/or antagonistic prophage interactions contribute to a complex network regulating toxin expression.

**Conclusion.** In summary, we characterized and sequenced the first genome of a *pac*-type *Siphoviridae* phage infecting *C. difficile*. In addition, our data strongly suggest that  $\phi$ CD38-2 replicates as a circular plasmid and does not integrate into the chromosome of its host. Phage  $\phi$ CD38-2 is able to infect several isolates of the hypervirulent epidemic strain NAP1/027, which recently caused severe outbreaks in North America and

Europe. Complete genome sequencing did not reveal the presence of identifiable virulence factors, but lysogenization of a NAP1/027 isolate with  $\phi$ CD38-2 led to increased *in vitro* toxin production through increased transcription of all PaLoc genes. Because  $\phi$ CD38-2 has the capacity to alter virulence-associated phenotypes through modulation of toxin expression, this phage represents a very interesting model to study phage-host interactions. The impacts of prophages in this clinically important pathogen remain relatively unexplored, and our study warrants further research in this area.

#### ACKNOWLEDGMENTS

We are grateful to Louis Valiquette for providing clinical isolates of *C. difficile*. We also thank Pier-Luc Dudemaine for helping with the host range analysis.

This study was supported by the Centre de Recherche Clinique Étienne-Le Bel, by a discovery grant from the Natural Sciences and Engineering Council of Canada (NSERC), and by a seed grant from the Canadian Institutes of Health Research (CIHR).

L.-C.F. is a research scholar from the Fonds de la Recherche en Santé du Québec (FRSQ).

#### REFERENCES

- Ackermann, H. 2007. 5500 phages examined in the electron microscope. *Arch. Virol.* **152**:227–243.
- Altschul, S., et al. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res.* **25**:3389–3402.
- Bidet, P., F. Barbut, V. Lalande, B. Burghoffer, and J. Petit. 1999. Development of a new PCR-ribotyping method for *Clostridium difficile* based on ribosomal RNA gene sequencing. *FEMS Microbiol. Lett.* **175**:261–266.
- Bourhy, P., et al. 2005. Complete nucleotide sequence of the LE1 prophage from the spirochete *Leptospira biflexa* and characterization of its replication and partition functions. *J. Bacteriol.* **187**:3931–3940.
- Brussow, H., C. Canchaya, and W. Hardt. 2004. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. *Microbiol. Mol. Biol. Rev.* **68**:560–602.
- Curry, S., et al. 2007. *tcdC* genotypes associated with severe TcdC truncation in an epidemic clone and other strains of *Clostridium difficile*. *J. Clin. Microbiol.* **45**:215–221.
- Dei, R. 1989. Observations on phage-typing of *Clostridium difficile*: preliminary evaluation of a phage panel. *Eur. J. Epidemiol.* **5**:351–354.
- Reference deleted.
- Dupuy, B., R. Govind, A. Antunes, and S. Matamouros. 2008. *Clostridium difficile* toxin synthesis is negatively regulated by TcdC. *J. Med. Microbiol.* **57**:685–689.
- Dupuy, B., and A. Sonenshein. 1998. Regulated transcription of *Clostridium difficile* toxin genes. *Mol. Microbiol.* **27**:107–120.
- Fortier, L., A. Bransi, and S. Moineau. 2006. Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of *Lactococcus lactis*. *J. Bacteriol.* **188**:6101–6114.
- Fortier, L., and S. Moineau. 2007. Morphological and genetic diversity of temperate phages in *Clostridium difficile*. *Appl. Environ. Microbiol.* **73**:7358–7366.
- Fortier, L., and S. Moineau. 2009. Phage production and maintenance of stocks, including expected stock lifetimes. *Methods Mol. Biol.* **501**:203–219.
- Goh, S., B. Chang, and T. Riley. 2005. Effect of phage infection on toxin production by *Clostridium difficile*. *J. Med. Microbiol.* **54**:129–135.
- Goh, S., P. Ong, K. Song, T. Riley, and B. Chang. 2007. The complete genome sequence of *Clostridium difficile* phage  $\{\phi\}$ C2 and comparisons to  $\{\phi\}$ CD119 and inducible prophages of CD630. *Microbiology* **153**:676–685.
- Goh, S., T. Riley, and B. Chang. 2005. Isolation and characterization of temperate bacteriophages of *Clostridium difficile*. *Appl. Environ. Microbiol.* **71**:1079–1083.
- Govind, R., J. Fralick, and R. Rolfe. 2006. Genomic organization and molecular characterization of *Clostridium difficile* bacteriophage  $\{\Phi\}$ CD119. *J. Bacteriol.* **188**:2568–2577.
- Govind, R., G. VEDIYAPPAN, R. Rolfe, B. Dupuy, and J. Fralick. 2009. Bacteriophage-mediated toxin gene regulation in *Clostridium difficile*. *J. Virol.* **83**:12037–12045.
- Gravel, D., et al. 2009. Health care-associated *Clostridium difficile* infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program study. *Clin. Infect. Dis.* **48**:568–576.
- Horgan, M., et al. 2010. Genome analysis of the *Clostridium difficile* phage PhiCD6356, a temperate phage of the *Siphoviridae* family. *Gene* **462**:34–43.
- Hundsberger, T., et al. 1997. Transcription analysis of the genes *tcdA-E* of the pathogenicity locus of *Clostridium difficile*. *Eur. J. Biochem.* **244**:735–742.



22. **Kuijper, E., B. Coignard, and P. Tull.** 2006. Emergence of *Clostridium difficile*-associated disease in North America and Europe. *Clin. Microbiol. Infect.* **12**(Suppl. 6):2–18.
23. **Lepiae, R., A. Hebrant, S. J. Wodak, and A. Toussaint.** 2004. ACLAME: a CLAssification of Mobile genetic Elements. *Nucleic Acids Res.* **32**:D45–D49.
24. **Loo, V., et al.** 2005. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N. Engl. J. Med.* **353**:2442–2449.
25. **Lucchini, S., F. Desiere, and H. Brussow.** 1999. Comparative genomics of *Streptococcus thermophilus* phage species supports a modular evolution theory. *J. Virol.* **73**:8647–8656.
26. **Lucchini, S., F. Desiere, and H. Brussow.** 1999. Similarly organized lysogeny modules in temperate *Siphoviridae* from low GC content gram-positive bacteria. *Virology* **263**:427–435.
27. **MacCannell, D. R., et al.** 2006. Molecular analysis of *Clostridium difficile* PCR ribotype 027 isolates from eastern and western Canada. *J. Clin. Microbiol.* **44**:2147–2152.
28. **Mahony, D., P. Bell, and K. Easterbrook.** 1985. Two bacteriophages of *Clostridium difficile*. *J. Clin. Microbiol.* **21**:251–254.
29. **Mani, N., and B. Dupuy.** 2001. Regulation of toxin synthesis in *Clostridium difficile* by an alternative RNA polymerase sigma factor. *Proc. Natl. Acad. Sci. U. S. A.* **98**:5844–5849.
30. **Mani, N., et al.** 2002. Environmental response and autoregulation of *Clostridium difficile* TxeR, a sigma factor for toxin gene expression. *J. Bacteriol.* **184**:5971–5978.
31. **Marston, A., and J. Errington.** 1999. Dynamic movement of the ParA-like Soj protein of *B. subtilis* and its dual role in nucleoid organization and developmental regulation. *Mol. Cell* **4**:673–682.
32. **Matamouros, S., P. England, and B. Dupuy.** 2007. *Clostridium difficile* toxin expression is inhibited by the novel regulator TcdC. *Mol. Microbiol.* **64**:1274–1288.
33. **Matte, I., et al.** 2009. Anti-apoptotic proteins Bcl-2/Bcl-XL inhibit *Clostridium difficile* toxin A-induced cell death in human epithelial cells. *Infect. Immun.* **77**:5400–5410.
34. **Mayer, M. J., A. Narbad, and M. J. Gasson.** 2008. Molecular characterization of a *Clostridium difficile* bacteriophage and its cloned biologically active endolysin. *J. Bacteriol.* **190**:6734–6740.
35. **Moineau, S., S. Pandian, and T. R. Klaenhammer.** 1994. Evolution of a lytic bacteriophage via DNA acquisition from the *Lactococcus lactis* chromosome. *Appl. Environ. Microbiol.* **60**:1832–1841.
36. **Murray, R., D. Boyd, M. Mulvey, P. Levett, and M. Alfa.** 2009. Truncation in the *tcdC* region of the *Clostridium difficile* PathLoc of clinical isolates does not predict increased biological activity of toxin B or toxin A. *BMC Infect. Dis.* **9**:103.
37. **Nagy, E., and J. Foldes.** 1991. Electron microscopic investigation of lysogeny of *Clostridium difficile* strains isolated from antibiotic-associated diarrhea cases and from healthy carriers. *APMIS* **99**:321–326.
38. **Pepin, J., L. Valiquette, and B. Cossette.** 2005. Mortality attributable to nosocomial *Clostridium difficile*-associated disease during an epidemic caused by a hypervirulent strain in Quebec. *CMAJ* **173**:1037–1042.
39. **Sebahia, M., et al.** 2006. The multidrug-resistant human pathogen *Clostridium difficile* has a highly mobile, mosaic genome. *Nat. Genet.* **38**:779–786.
40. **Sell, T., D. Schaberg, and F. Fekety.** 1983. Bacteriophage and bacteriocin typing scheme for *Clostridium difficile*. *J. Clin. Microbiol.* **17**:1148–1152.
41. **Stabler, R., et al.** 2009. Comparative genome and phenotypic analysis of *Clostridium difficile* 027 strains provides insight into the evolution of a hypervirulent bacterium. *Genome Biol.* **10**:R102.
42. **Tan, K., B. Wee, and K. Song.** 2001. Evidence for holin function of *tcdE* gene in the pathogenicity of *Clostridium difficile*. *J. Med. Microbiol.* **50**:613–619.
43. **Verdoorn, B., et al.** 2010. High prevalence of *tcdC* deletion-carrying *Clostridium difficile* and lack of association with disease severity. *Diagn. Microbiol. Infect. Dis.* **66**:24–28.
44. **Voth, D. E., and J. D. Ballard.** 2005. *Clostridium difficile* toxins: mechanism of action and role in disease. *Clin. Microbiol. Rev.* **18**:247–263.
45. **Warny, M., et al.** 2005. Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and Europe. *Lancet* **366**:1079–1084.